SEEG-Tx System (STX-SYS-001)
Dixi Medical · Decision date Oct 29, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for the SEEG-Tx® System (STX-SYS-001), submitted by Dixi Medical of Marchaux-Chaudefontaine, France, under 510(k) number K260337. The decision date is 2026-10-29; the application was received 02/02/2026. The device falls under regulation 882.4400 with classification product code GXD and subsequent product code GXI, and the regulation medical specialty and 510k review panel are both listed as Neurology. A 510(k) SESE decision is a clearance, not a PMA approval.
The record identifies the device classification name as Generator, Lesion, Radiofrequency and the submission type as Traditional, with no third-party review, no combination product status and no authorized Predetermined Change Control Plan. The correspondent is Medtech Regulatory Strategist, Inc. The source does not describe the device's components, the specific changed item, indications for use, or the predicate device, so those details remain unknown here and would need the linked summary document.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 29, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260337
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Dixi Medical
- Product code
- GXD
- Decision code
- SESE
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Generator, Lesion, Radiofrequency.
- Applicant
- Dixi Medical
- Product code
- GXD
- FDA device class
- 2
FDA decision timeline
K260337 received
Application receipt date recorded by FDA.
K260337 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Dixi Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Marchaux-Chaudefontaine
Sources and methodology
- Original FDA record: K260337
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records